京新药业(002020) - 2017 Q3 - 季度财报

Financial Performance - Operating revenue for the period was CNY 547,396,375.89, representing a 19.51% increase year-on-year[8]. - Net profit attributable to shareholders was CNY 79,084,430.13, up 27.34% compared to the same period last year[8]. - Net profit after deducting non-recurring gains and losses was CNY 68,536,423.08, an increase of 18.65% year-on-year[8]. - Basic earnings per share rose by 27.57% to CNY 0.1240[8]. - The weighted average return on equity increased by 2.99% to 9.56%[8]. - The company expects a net profit attributable to shareholders for 2017 to range between CNY 254.33 million and CNY 275.53 million, representing a growth of 20.00% to 30.00% compared to 2016[27]. Assets and Shareholder Equity - Total assets increased by 35.96% to CNY 4,473,978,440.23 compared to the end of the previous year[8]. - Net assets attributable to shareholders increased by 53.60% to CNY 3,657,155,133.70 compared to the end of the previous year[8]. - The total number of ordinary shareholders at the end of the reporting period was 25,243[12]. - The largest shareholder, Lü Gang, holds 20.11% of the shares, with 148,018,996 shares, of which 110,050,000 are pledged[12]. - Undistributed profits grew by 38.72% to CNY 663.56 million, mainly driven by an increase in net profit[20]. Current Assets and Liabilities - Prepayments increased by 162.47% to CNY 392.71 million, mainly due to an increase in advance payments for raw materials[16]. - Interest receivables rose by 115.10% to CNY 73.70 million, primarily due to increased interest accruals on financial products[17]. - Other current assets surged by 159.10% to CNY 1,618.25 million, mainly attributed to an increase in financial products[18]. - Financial expenses skyrocketed by 1687.95% to CNY 2.68 million, primarily due to increased foreign exchange losses[22]. - Investment income rose by 155.73% to CNY 21.35 million, mainly from increased returns on bank financial products[22]. Cash Flow - The net cash flow from operating activities was negative at CNY -38,586,250.29, a decrease of 124.21% compared to the previous year[8].